Two people indicted in Florida over counterfeit Ozempic, and if you're on this drug, your first thought goes straight to the pen in your fridge. This is GLP-1 Daily. Today, an alleged smuggling scheme, plus Novo and Lilly swinging dueling datasets in Milan. So whose numbers do you actually believe? And how to tell if your prescription is the real thing. We start in Florida. If today's show was useful, follow us wherever you're listening — the next one will be waiting. The Front Page writes:
Federal authorities have charged two Indian nationals with orchestrating an international conspiracy to smuggle counterfeit versions of the weight-loss medication Ozempic into the United States. Swapnadip Roy, 33, made his initial appearance in U.S. District Court in Tampa, Florida, on Tuesday following his extradition from Italy. His alleged co-conspirator, 37-year-old Vicky Ramancha, remains at large.
Swapnadip Roy, thirty-three, made his first appearance in federal court in Tampa on Tuesday, fresh off an extradition from Italy. His alleged co-conspirator, Vicky Ramancha, is still at large. And everything in that indictment is an allegation until a court says otherwise. And put this one in its own bin. There's no licensed pharmacy anywhere in this story. Prosecutors say it's fake Ozempic from unauthorized manufacturers in China, shipped with fake inserts, fake pen labels, even fake needles. Allegedly still moving months after the FDA's own December 2023 counterfeit warning. What gets me is the sales pitch. The indictment says they told U.S. distributors that a lower price meant cutting corners. One March 2024 shipment was about eleven thousand units. July '23 to April '24. So who was at the far end of that chain holding the pen? The patient a plan had already turned down? That's a fair question to ask. But I'm not going to answer it for the prosecutors. The charges are about distributors. Until somebody traces those eleven thousand units to actual patients, I'll leave the buyers out of it. Finviz writes:
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity
So twelve milligrams of retatrutide over eighty weeks gets you forty-nine point six pounds, twenty point eight percent. And every single person in TRIUMPH-2 had type 2 diabetes. Which is historically the harder group to move on these drugs, so that number is real. And it went to The Lancet the same day as the PR Newswire blast. I'll be reading the paper, not the bullet points. Because NBC's already running 'up to sixty pounds, biggest ever in a diabetes trial.' Sixty is the BMI-thirty-five-and-up subgroup. The trial-wide average is forty-nine six. Keep an eye on that 'up to.' Here's where I get stuck, though. This is the population payers already cover. A blowout result in the diabetes arm makes a plan comfortable covering diabetes. Does it move anything for someone with a BMI of thirty-eight and a perfectly normal A1C? Yeah, no. It's still investigational. There's no tier to fight over yet. Sure, not yet. But tiers get written off data exactly like this. So when retatrutide lands on a formulary, I want to know which trial arm the plan quotes to set the criteria. Here's Fraiser Kansteiner at Fierce Pharma:
In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with dueling datasets on oral and injectable GLP-1s. Among the mix of real-world evidence and indirect comparisons, Novo vouched for Ozempic’s edge at lowering the risk of serious cardiovascular events when compared to patients who switched to Lilly’s diabetes rival Mounjaro, harkening to a familiar perk of its semaglutide franchise.
So Milan's first day hands us three comparisons from two companies, and not one head-to-head trial. Novo says Ozempic beats Mounjaro on serious cardiac events. Lilly says Foundayo beats the Wegovy pill, and Zepbound beats high-dose Wegovy. And every one of those numbers came off a company slide. Novo's is real-world data on patients who switched to Mounjaro. Why did they switch? Sicker, cheaper plan, side effects? That group isn't randomized. Lilly's pair are indirect comparisons. Fine for a hypothesis. Nowhere near a verdict. Here's what bugs me, though. A pharmacy benefit manager doesn't need a verdict. It needs a citation. Want Ozempic first? Quote Novo's cardiac slide. Want Zepbound first? Quote Lilly's weight chart. Either way the patient eats the step-therapy order. Right, and that's why I'd rather see these on a podium with the methods than in a press kit. Pair it with the retatrutide release we just hit and it's a week of big numbers that nobody outside the companies has checked. I'll get excited when a journal does. EurekAlert! writes:
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway. This regulator-mandated post authorisation study, funded by Novo, the manufacturer of semaglutide, is presented by Professor Anton Pottegård, University of Southern Denmark, Odense, Denmark, and colleagues.
Ninety-seven thousand four hundred sixty-four semaglutide users across registries in Denmark, Sweden and Norway, and no pancreatic cancer link. The funder's right there in the release's opening paragraph, too: Novo. And I'll take it. Honestly, as somebody with a pen in her fridge, I'll take it. Regulators demanded this study as a condition back at approval, so this is the check doing its job. But it's a podium talk in Milan and not a journal paper yet, and short follow-up can't rule out a cancer that takes a decade to show. Look at the comparator, too. It's semaglutide against other non-incretin diabetes drugs. So this is a diabetes cohort, and the patient on it purely for weight management is borrowing somebody else's safety data. Partly, yeah. It's the same molecule, though, so I wouldn't wave it off. After the dueling Novo-Lilly decks we just went through, this is the least self-serving thing Novo brought to Milan, and it's still Novo's money. So if counterfeit Ozempic can get into the U.S. supply chain, what can a patient actually check? And what should you do if something about a prescription looks off? First thing: a familiar-looking box, even a real lot number, doesn't prove a pen is genuine. The FDA says it seized dozens of counterfeit one-milligram Ozempic units that had been distributed illegally outside Novo Nordisk's authorized supply chain, and they carried lot number PAR1229. That's also an authentic lot number. So you can't authenticate a pen from the packaging alone. On the case itself, the Justice Department has charged two people in an alleged transnational scheme selling counterfeit Ozempic to U.S. distributors at deep discounts, and again, those are allegations, not findings of guilt. If a product, a pharmacy, or the packaging seems off, the FDA's warning is clear: don't use a suspected counterfeit, and report the product problem to the agency. And before you do anything else with that prescription, check with your prescriber or pharmacist. Don't lean on an online seller or the look of the box. So even a real lot number might not settle it. Does that mean patients should treat every compounded GLP-1 as counterfeit? No. Counterfeit and compounded aren't the same thing. This FDA alert is about products falsely sold as Ozempic. The practical move is to be careful about the source, especially offers that don't clearly connect you with a prescriber and a pharmacy, and to bring questions about any GLP-1 product to your prescriber or pharmacist. Watch for more FDA safety alerts and enforcement updates as investigators dig into the alleged scheme. Got feedback, a story idea, or a correction? Email us at glp1daily at lantern podcasts dot com. Your notes help make GLP-1 Daily more useful and more accurate.
We're watching the EASD annual meeting in Milan, which runs through October 2, for more GLP-1 and incretin datasets before it wraps.
Links to every story are in the show notes, so dig into whichever ones grabbed you. That's GLP-1 Daily for today. We'll be back tomorrow. This is a Lantern Podcast.